Constellium SE is a global manufacturer of aluminium rolled products, extruded products, and structural parts based on a large variety of advanced alloys. Constellium's C-TEC research center has been credited for advancing technology in the field of advanced aluminium alloys. Constellium primarily serves the aerospace, automotive, and packaging sectors. Large clients include Mercedes-Benz, Audi, BMW, Fiat Chrysler Automotive, Ford, Airbus, Boeing, and Bombardier.
Gas burners are essential in industrial furnaces, yet their efficiency often ranges from only 20
Lightweight materials are essential in reducing the overall weight and improving the efficiency and performance of ICE and electric vehicles. The use of aluminum alloys is critical in transitioning to a more energy sustainable and environmentally friendly future. The accessible combinations of high modulus to density and strength to weight ratios, as well as their excellent thermal conductivity, make them an ideal solution for overall weight reduction in vehicles, thereby improving fuel efficiency and reducing emissions. Aluminum alloys with high strength and lifetime thermal stability have been industrialized for usage in brake rotor applications. Amongst the most used aluminum alloys with high thermal stability are 2618-T8 and 4032-T6 for use in aerospace and automotive industries, respectively. However, when it comes to prolonging the life of a product at temperatures that exceed 200°C, the properties of these alloys will quickly degrade within the first 300 hours of exposure. Therefore, a new generation of Al-Cu-Mg alloys was developed to further optimize properties and to provide the maximum strength at elevated temperatures with the highest thermal conductivity. Adequate testing exposing them to temperatures up to 300°C for an extended period of time showed that they do not demonstrate significant loss in mechanical strength. In addition, simulations to predict the aluminum strength loss during braking were generated and results are cross compared to cast iron, SS and 304L.
Aluminum alloys commonly contain Si as an impurity or alloying element. The energetic behavior of Si within multiple compounds and solutions is incorporated inside thermochemical packages, such as FactSage. This tool allows determining the Si partitioning within complex multiphasic systems. Recent experimental research suggests that Si can be found within Al 3 Zr-based intermetallics. Nevertheless, current FactSage databases do not consider the potential substitution of Si within the Al 3 Zr-D0 23 solid solution. In this work, Si substitution within the (Al,Si) 3 Zr-D0 23 phase was investigated by means of first-principles calculations. Replacement of Al atoms by Si resulted in a negative enthalpy of mixing, indicating that Si substitution is energetically enabled. The density of states (DOS) for both a Si-diluted (Al,Si) 3 Zr and a non-Si-doped (Al 3 Zr) simulation cells were analyzed. It is shown that (even in dilution), Si significantly impacts the electronic structure of the Al 3 Zr-D0 23 structure. Specifically, the presence of Si localizes electrons in the p orbital of Al, and increases the DOS of the d xy , d xz , and d yz sub-orbitals of Zr at low energies. Thus, yielding a coupled effect that stabilizes the D0 23 intermetallic. These findings are a benchmark for the future integration of a Si-based end-member within the Al 3 Zr-D0 23 solid solution of FactSage databases.
e13647 Background: Oncology-relevant measures of disease and treatment support earlier detection, accelerated drug development, and inform treatment pathways. To advance access to transformative treatments for people with cancer, especially those for early-stage cancers where medical intervention has the greatest opportunity to impact the course of the disease, the cancer community identified seven principles that support the evolution of value assessment frameworks. Here we summarize the five key principles. Methods: A group of 24 cancer community experts (9 oncologists, 6 patient advocacy leaders, 1 former regulator, 6 former payers, and 4 health economists) from 14 countries came together to discuss and build consensus on oncology-relevant value principles. Over five months, the expert group engaged via surveys, virtual discussion panels, and interviews. Results: The expert group developed seven consensus principles covering two areas: oncology-relevant endpoints to assess the value of treatments; and additional important value components and how they can be integrated into value assessments. The key 5 principles were oncology-relevant endpoints assessing clinical effectiveness, including the following three items. 1) Consider oncology-relevant endpoints, other than Overall Survival (OS), with intrinsic value for decision-making e.g., Event-, Disease-, or Relapse-Free Survival. 2) Continue to build evidence for endpoints that indicate treatment efficacy earlier e.g., pathologic Complete Response. 3) Develop evidence for the next generation of predictive measures that detect and monitor disease, e.g., circulating tumor DNA and Minimal Residual Disease. Additional value components supporting patient access include the following two items. 1) Use managed entry (type of access) agreements supported by ongoing real world evidence collection to help address decision-maker (regulator and Health Technology Assessment body) evidence needs. 2) Routinely use Patient Reported Outcomes (PROs) in value assessments. Conclusions: To achieve the common goal of all cancer community stakeholders—improved outcomes for people with cancer—collaboration across the cancer community is essential to define how value is assessed, especially for early-stage cancer treatments. This is particularly important since mature OS data is not always available during initial decision-making, and decision-makers need to evolve which are the most appropriate endpoints. This supports measuring clinical impact, but also broader social, financial and ethical impact for patients, caregivers, healthcare systems, society, and the economy (not considered in this abstract). To achieve these goals, the expert group recommends: 1) increasing awareness and systematically engaging people with cancer in value assessments, 2) leveraging PROs in those assessments, and 3) further validation in clinical trials of oncology-relevant endpoints that could provide an earlier indication of clinical outcomes.